Display options
Cite
Ombredane AS, Silva VRP, Andrade LR, et al. . Front Oncol. 2021;11:612903doi: 10.3389/fonc.2021.612903.
Ombredane, A. S., Silva, V. R. P., Andrade, L. R., Pinheiro, W. O., Simonelly, M., Oliveira, J. V., Pinheiro, A. C., Gonçalves, G. F., Felice, G. J., Garcia, M. P., Campos, P. M., Luz, G. V. S., & Joanitti, G. A. (2021). . Frontiers in oncology, 11612903. https://doi.org/10.3389/fonc.2021.612903
Ombredane, Alicia S, et al. "." Frontiers in oncology vol. 11 (2021): 612903. doi: https://doi.org/10.3389/fonc.2021.612903
Ombredane AS, Silva VRP, Andrade LR, Pinheiro WO, Simonelly M, Oliveira JV, Pinheiro AC, Gonçalves GF, Felice GJ, Garcia MP, Campos PM, Luz GVS, Joanitti GA. . Front Oncol. 2021 Mar 09;11:612903. doi: 10.3389/fonc.2021.612903. eCollection 2021. PMID: 33767985; PMCID: PMC7986721.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2021 Mar 09;11:612903. doi: 10.3389/fonc.2021.612903. eCollection 2021.

[No title available]

Frontiers in oncology

Alicia S Ombredane, Vitória R P Silva, Laise R Andrade, Willie O Pinheiro, Mayara Simonelly, Jaqueline V Oliveira, Andréia C Pinheiro, Gabriel F Gonçalves, Gisela J Felice, Mônica P Garcia, Patrícia M Campos, Glécia V S Luz, Graziella A Joanitti

Affiliations

  1. Laboratory of Bioactive Compounds and Nanobiotechnology (LBCNano), University of Brasilia, Brasilia, Brazil.
  2. Post-Graduation Program in Nanoscience and Nanobiotechnology, Institute of Biological Sciences, University of Brasilia, Brasilia, Brazil.
  3. Department of Genetics & Morphology, Institute of Biological Sciences, University of Brasilia, Brasilia, Brazil.
  4. Post-Graduation Program in Sciences and Technologies in Health, Faculty of Ceilandia, University of Brasilia, Brasilia, Brazil.
  5. Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
  6. Pharmaceutical Sciences Department, State University of Ponta Grossa, Parana, Brazil.
  7. Post-Graduate Program in Biomedical Engineering-PPGEB, Faculty of Gama-FGA, University of Brasilia, Brasilia, Brazil.
  8. Health Technology Assessment Center-NATS/UnB, University of Brasília, Brasilia, Brazil.

PMID: 33767985 PMCID: PMC7986721 DOI: 10.3389/fonc.2021.612903

Abstract

Breast cancer is one of the most prevalent types of malignant tumors in the world, resulting in a high incidence of death. The development of new molecules and technologies aiming to apply more effective and safer therapy strategies has been intensively explored to overcome this situation. The association of nanoparticles with known antitumor compounds (including plant-derived molecules such as curcumin) has been considered an effective approach to enhance tumor growth suppression and reduce adverse effects. Therefore, the objective of this systematic review was to summarize published data regarding evaluations about efficacy and toxicity of curcumin nanoparticles (Cur-NPs) in

Copyright © 2021 Ombredane, Silva, Andrade, Pinheiro, Simonelly, Oliveira, Pinheiro, Gonçalves, Felice, Garcia, Campos, Luz and Joanitti.

Keywords: antitumor; apoptosis; breast cancer; curcumin; in vivo; nanoparticle; systematic review; toxicity

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Exp Ther Med. 2018 Aug;16(2):1266-1272 - PubMed
  2. Chem Biol Interact. 2020 Jan 5;315:108865 - PubMed
  3. BMC Health Serv Res. 2014 Nov 21;14:579 - PubMed
  4. Semin Cancer Biol. 2021 Feb;69:5-23 - PubMed
  5. Int J Mol Sci. 2019 Nov 30;20(23): - PubMed
  6. Artif Cells Nanomed Biotechnol. 2018;46(sup2):921-935 - PubMed
  7. Nat Rev Dis Primers. 2019 Sep 23;5(1):66 - PubMed
  8. Curr Cancer Drug Targets. 2005 Mar;5(2):117-29 - PubMed
  9. Int J Rheum Dis. 2019 Oct;22(10):1857-1862 - PubMed
  10. Nanomaterials (Basel). 2018 Nov 01;8(11): - PubMed
  11. Front Pharmacol. 2020 Sep 15;11:01021 - PubMed
  12. Int J Cancer. 2002 Mar 10;98(2):234-40 - PubMed
  13. Pharmaceutics. 2020 Jan 24;12(2): - PubMed
  14. J Mater Chem B. 2017 Sep 7;5(33):6762-6775 - PubMed
  15. PLoS Med. 2009 Jul 21;6(7):e1000097 - PubMed
  16. Nutrients. 2019 Oct 05;11(10): - PubMed
  17. Front Oncol. 2020 Jun 02;10:764 - PubMed
  18. Phytother Res. 2020 Aug;34(8):1992-2005 - PubMed
  19. Int J Oncol. 2020 Feb;56(2):480-493 - PubMed
  20. Int J Nanomedicine. 2015 Sep 28;10:6055-74 - PubMed
  21. Acta Biomater. 2020 Jun;109:244-253 - PubMed
  22. Colloids Surf B Biointerfaces. 2019 Dec 1;184:110515 - PubMed
  23. Nanoscale. 2017 Nov 2;9(42):16365-16374 - PubMed
  24. Artif Cells Nanomed Biotechnol. 2018;46(sup1):302-313 - PubMed
  25. Biochem Pharmacol. 2008 Dec 1;76(11):1340-51 - PubMed
  26. Curr Pharm Des. 2018;24(19):2121-2128 - PubMed
  27. Theranostics. 2020 Jun 25;10(17):7921-7924 - PubMed
  28. J Exp Clin Cancer Res. 2017 Jul 19;36(1):98 - PubMed
  29. Expert Rev Gastroenterol Hepatol. 2017 Feb;11(2):99-101 - PubMed
  30. Oncol Lett. 2018 Jun;15(6):9093-9100 - PubMed
  31. Biomaterials. 2014 Mar;35(10):3467-79 - PubMed
  32. Adv Healthc Mater. 2015 Jul 15;4(10):1496-501, 1423 - PubMed
  33. Cancer Lett. 1985 Nov;29(2):197-202 - PubMed
  34. Cancer Lett. 2017 Aug 1;400:325-335 - PubMed
  35. Cancer Metastasis Rev. 2019 Jun;38(1-2):25-49 - PubMed
  36. Anticancer Agents Med Chem. 2015;15(10):1285-96 - PubMed
  37. Eur J Pharmacol. 2010 Jul 10;637(1-3):16-21 - PubMed
  38. J Vis Exp. 2016 Aug 14;(114): - PubMed
  39. Dis Model Mech. 2017 Apr 1;10(4):359-371 - PubMed
  40. Biomed Res Int. 2015;2015:824746 - PubMed
  41. Mol Med Rep. 2019 Jun;19(6):5162-5168 - PubMed
  42. Pharm Res. 2020 Feb 18;37(3):56 - PubMed
  43. Nanomedicine (Lond). 2018 Jun;13(12):1495-1512 - PubMed
  44. Pharm Res. 2019 Dec 23;37(1):12 - PubMed
  45. Molecules. 2011 Jun 03;16(6):4567-98 - PubMed
  46. Crit Rev Food Sci Nutr. 2019;59(2):299-312 - PubMed
  47. Acta Biomater. 2019 Aug;94:320-329 - PubMed
  48. J Adv Res. 2019 Mar 01;18:161-172 - PubMed
  49. Pharmaceuticals (Basel). 2016 Nov 10;9(4): - PubMed
  50. Anticancer Res. 2015 Feb;35(2):599-614 - PubMed
  51. Adv Drug Deliv Rev. 2015 Aug 30;91:3-6 - PubMed
  52. ACS Biomater Sci Eng. 2019 May 13;5(5):2577-2586 - PubMed
  53. Mol Med Rep. 2019 Jan;19(1):23-29 - PubMed
  54. Bioconjug Chem. 2017 Jan 18;28(1):135-152 - PubMed
  55. Drug Deliv. 2017 Nov;24(1):1470-1481 - PubMed
  56. Biomaterials. 2017 Dec;147:53-67 - PubMed
  57. J Natl Cancer Inst. 2015 Mar 31;107(7): - PubMed
  58. JAMA. 2019 Jan 22;321(3):288-300 - PubMed
  59. J Control Release. 2010 Aug 3;145(3):182-95 - PubMed
  60. Mater Sci Eng C Mater Biol Appl. 2019 May;98:1252-1276 - PubMed
  61. Drug Deliv. 2016 May;23(4):1420-5 - PubMed
  62. BMC Med Res Methodol. 2014 Mar 26;14:43 - PubMed
  63. Drug Dev Ind Pharm. 2017 May;43(5):847-861 - PubMed
  64. J Nutr Sci. 2016 Apr 26;5:e17 - PubMed
  65. Biomater Sci. 2020 Jan 1;8(1):462-472 - PubMed
  66. Asian Pac J Cancer Prev. 2015;16(9):3917-22 - PubMed
  67. Nat Mater. 2020 May;19(5):566-575 - PubMed
  68. Pharmaceutics. 2020 Apr 17;12(4): - PubMed
  69. Curr Pharm Des. 2017;23(6):921-931 - PubMed
  70. Nanotechnol Rev. 2015 Apr;3(2):111-122 - PubMed
  71. Evid Based Complement Alternat Med. 2020 Jul 17;2020:2892917 - PubMed
  72. Int J Nanomedicine. 2019 Oct 15;14:8285-8302 - PubMed
  73. J Biomed Nanotechnol. 2016 Jul;12(7):1374-92 - PubMed
  74. PLoS Biol. 2020 Jul 14;18(7):e3000410 - PubMed
  75. ACS Nano. 2016 Aug 23;10(8):7738-48 - PubMed
  76. Int J Nanomedicine. 2020 Apr 30;15:2987-2998 - PubMed
  77. ACS Biomater Sci Eng. 2019 May 13;5(5):2595-2609 - PubMed

Publication Types